Compare UnitedHealth Group Inc (UNH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UnitedHealth Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? UnitedHealth Group Inc trades at $405.1 (market cap $361.00B), while Vertex Pharmaceuticals Incorporated trades at $524.77 (market cap $134.25B). The key difference: UnitedHealth Group Inc is far larger — about 2.7× Vertex Pharmaceuticals Incorporated's market cap, and UnitedHealth Group Inc pays a 2.31% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| UNH | VRTX | |
|---|---|---|
Market Cap | $361.00B | $134.25B |
Sector | Health | Health |
52-Week High | $436.35 | $529.65 |
52-Week Low | $259.02 | $376.62 |
Enterprise Value | $402.86B | $128.37B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UnitedHealth Group (UNH) trades at $408.74, showing modest daily gains of 0.41% amid a bearish technical signal. The company demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust analyst support (82.7% buy ratings). Recent developments include dividend payments and strategic initiatives to streamline pediatric care authorizations, positioning UNH well in the healthcare sector.
UNH presents a compelling investment case with strong cash flow generation and market leadership, though investors face risks from regulatory scrutiny and margin compression. The stock trades at a discount to analyst consensus target of $476.50, offering potential upside if operational improvements and growth initiatives materialize as projected.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
